Posted by Michael Wonder on 16 Dec 2020
Health Canada approves Venclexta (venetoclax) in combination with azacitidine or low dose cytarabine for untreated acute myeloid leukaemia
15 December 2020 - Health Canada's approval of Venclexta for newly diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from two Phase 3 trials - VIALE-A (M15-656) and VIALE-C (M16-043).
AbbVie announced today that Health Canada has approved Venclexta (venetoclax) in combination with azacitidine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukaemia in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
